Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance.
Oliver
O
Hantschel
D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive; D011743:Pyrimidines / Q000494:pharmacology*
C508526:GNF-2 compound; D011743:Pyrimidines; D016044:Fusion Proteins, bcr-abl